Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer

Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardeli, Chrysanthi, Zarogoulidis, Paul, Romanidis, Konstantinos, Oikonomou, Panagoula, Sapalidis, Konstantinos, Huang, Haidong, Bai, Chong, Hohenforst-Schmidt, Wolfgang, Tsakiridis, Kosmas, Zaric, Bojan, Perin, Branislav, Ioannidis, Aris, Baka, Sofia, Drevelegas, Konstantinos, Kosmidou, Maria, Kosmidis, Christoforos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596337/
https://www.ncbi.nlm.nih.gov/pubmed/33145157
http://dx.doi.org/10.1016/j.rmcr.2020.101258
Descripción
Sumario:Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.

Ejemplares similares